A study published in JNCCN—Journal of the National Comprehensive Cancer Network demonstrated that among all patients with neuroendocrine tumors, the risk of dying of cancer was higher than that of dying of other causes—but mortality varies by primary tumor site.
Last week, FDA granted accelerated approval to Replimune Group Inc. for it’s biologic, RP1 (vusolimogene oderparepvec), following the FDA Cellular, Tissue, and Gene Therapies Advisory Committee’s 10:3 vote in support of the biologic in combination with nivolumab for the treatment of advanced melanoma in patients who have progressed on prior anti-PD-1 therapy.
